Silexion Therapeutics prices $2.5M public offering at $0.65 per share

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced the pricing of a public offering of 3,846,161 ordinary shares, or ordinary share equivalents, along with series E warrants to purchase up to 3,846,161 ordinary shares, at a combined price of $0.65 per share and accompanying warrant.

The series E warrants carry an exercise price of $0.65 per share, are exercisable immediately upon issuance, and expire five years from the date of issuance. The offering is expected to close on or about Aug. 13, 2026, subject to customary closing conditions.

Gross proceeds are expected to be approximately $2.5 million before placement agent fees and other expenses. The company said it intends to use net proceeds to advance its SIL204 clinical trial and for general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The securities are being offered pursuant to a registration statement on Form S-1 declared effective by the Securities and Exchange Commission on Aug. 11, 2026.

Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies targeting KRAS-driven cancers. Its lead product candidate, SIL204, is a small interfering RNA currently in a Phase 2/3 clinical trial at Tel Aviv Sourasky Medical Center for locally advanced pancreatic cancer.

You May Also Be Interested In

• Leader's Advantage Acquisition Corp. closes $150M IPO on Nasdaq
• Sellas presents preclinical SLS009 pancreatic cancer data at AACR
• MVB Bank partners with DingoBlu on mobile banking platform